Want to see TSE:OVAT full AI Analyst Report?
OVAT Stock Chart & Stats
C$0.02
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.02
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.05
Previous CloseN/A
Volume54.36K
Average Volume (3M)3.74K
Market Cap
C$1.15M
Enterprise ValueC$0.86
Total Cash (Recent Filing)C$13.22K
Total Debt (Recent Filing)C$292.14K
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Nov 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding38,441,680
10 Day Avg. Volume3,400
30 Day Avg. Volume3,744
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-0.98
Price to Sales (P/S)20.98
P/FCF Ratio-18.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Transdermal PlatformOwning a proprietary transdermal delivery platform provides a durable product differentiation and technical barrier to entry. It supports multiple end-markets (cosmetic and therapeutic), enables vertically integrated finished products, and underpins long-term licensing or co-development opportunities if commercial execution improves.
B2B Monetization PotentialThe ability to monetize the platform via B2B deals or licensing offers a structural path to scale without proportional capex. Successful partnerships could deliver recurring royalties, diversify revenue channels, and accelerate adoption of the Invibe technology even if direct-to-consumer sales remain limited.
Improving Cash Burn TrendA sustained reduction in cash burn across multiple years lengthens runway and reduces near-term financing pressure. While cash flow remains negative, consistent moderation of outflows gives management more time to commercialize products or complete partnerships without immediately diluting shareholders or restructuring operations.
Bears Say
Tiny And Contracting Revenue BaseA very small and declining revenue base undermines operational scalability and market credibility. With only ~$66k TTM sales and recent contraction, the company lacks the sales scale to absorb fixed costs, invest in growth, or demonstrate product-market fit to partners, making durable recovery more difficult.
Negative Gross ProfitSelling below cost is structurally unsustainable: negative gross profit erodes any operating leverage and requires either price increases, material cost reductions, or scale to reverse. Persistent negative gross margins constrain cash generation and force reliance on external capital or strategic changes to the business model.
Deeply Negative Equity / Solvency RiskDeeply negative equity signals accumulated losses that exceed assets and materially weakens financial flexibility. This heightens insolvency risk, limits access to traditional financing, increases dilution risk from equity raises, and can force restructuring if losses persist, restricting long-term strategic options.
Ovation Science News
OVAT FAQ
What was Ovation Science Inc’s price range in the past 12 months?
Ovation Science Inc lowest stock price was C$0.01 and its highest was C$0.05 in the past 12 months.
What is Ovation Science Inc’s market cap?
Ovation Science Inc’s market cap is C$1.15M.
When is Ovation Science Inc’s upcoming earnings report date?
Ovation Science Inc’s upcoming earnings report date is Nov 30, 2026 which is in 104 days.
How were Ovation Science Inc’s earnings last quarter?
Ovation Science Inc released its earnings results on Aug 11, 2026. The company reported -C$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Ovation Science Inc overvalued?
According to Wall Street analysts Ovation Science Inc’s price is currently Overvalued.
Does Ovation Science Inc pay dividends?
Ovation Science Inc does not currently pay dividends.
What is Ovation Science Inc’s EPS estimate?
Ovation Science Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ovation Science Inc have?
Ovation Science Inc has 38,441,680 shares outstanding.
What happened to Ovation Science Inc’s price movement after its last earnings report?
Ovation Science Inc reported an EPS of -C$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ovation Science Inc?
Currently, no hedge funds are holding shares in TSE:OVAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ovation Science Inc
Ovation Science Inc. specializes in the creation of cannabis and hemp-based products, distributed across Canada, the United States, and Mexico. A cornerstone of its offerings is Invisicare, a patented drug delivery technology employed in topical and transdermal skincare formulations. This system integrates hemp seed oil and cannabis, underpinning the company's Ovation and BASKiN brands. Additionally, Ovation Science provides a diverse product portfolio including Invibe MD for CBD-infused health and wellness, ARLO CBD for skincare, and DermSafe for hand sanitizers. The company possesses sublicenses for its cannabis product lines and utilizes its Lighthouse initiative to engage with licensed dispensaries throughout the United States. Founded in 2017, Ovation Science Inc. is based in Vancouver, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Vext Science
―
BioNxt Solutions
―